Pelizaeus-Merzbacher disease in female carriers

Pelizaeus-Merzbacher disease (PMD) in female carriers refers to the neurological manifestations that can occur in women who carry a heterozygous pathogenic variant in the PLP1 gene, located on the X chromosome. While PMD classically affects males as an X-linked recessive leukodystrophy, female carriers can develop symptoms ranging from mild to moderate in severity, a condition sometimes referred to as manifesting carrier status of PMD. The PLP1 gene encodes proteolipid protein 1, which is essential for the formation and maintenance of myelin in the central nervous system. Skewed X-inactivation is thought to be a major mechanism underlying symptom expression in carrier females. Female carriers may develop progressive neurological symptoms that typically emerge later than in affected males, often in childhood, adolescence, or adulthood. Key clinical features can include progressive spastic paraparesis (stiffness and weakness of the legs), mild cognitive difficulties, ataxia (impaired coordination), and peripheral neuropathy. Some carriers may also experience autonomic dysfunction and mild white matter abnormalities visible on brain MRI. The severity is highly variable; some carriers remain asymptomatic throughout life, while others develop significant disability. There is currently no cure or disease-modifying treatment for PMD in female carriers. Management is supportive and symptomatic, focusing on physical therapy, occupational therapy, and assistive devices to maintain mobility and function. Spasticity may be managed with medications such as baclofen or tizanidine. Genetic counseling is recommended for carrier females to discuss reproductive risks and the variable expressivity of the condition. Ongoing research into myelin repair strategies and gene therapy offers hope for future therapeutic options.

Common questions about Pelizaeus-Merzbacher disease in female carriers